Evidence map›Paper›PMID 41021261›Full record

ArticleBriefings in bioinformatics2025

Advancing ADMET prediction through multiscale fragment-aware pretraining with MSformer-ADMET.

Huihui Liu, Bingjie Zhu, Shuyang Nie, Haoran Li, Yugang Lin, Tianyi Ma, Xin Shao, Qian Chen, Minjie Shen, Yanrong Zheng and 2 more

Abstract read
In one paragraph

Article in Briefings in bioinformatics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Huihui LiuDepartment of Pharmaceutical Sciences, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou, 310058, China.ORCID 0009-0003-7421-3316
Bingjie ZhuDepartment of Pharmaceutical Sciences, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou, 310058, China.
Shuyang NieDepartment of Pharmaceutical Sciences, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou, 310058, China.
Haoran LiDepartment of Pharmaceutical Sciences, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou, 310058, China.
Yugang LinDepartment of Pharmaceutical Sciences, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou, 310058, China.
Tianyi MaDepartment of Pharmaceutical Sciences, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou, 310058, China.
Xin ShaoDepartment of Pharmaceutical Sciences, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou, 310058, China.ORCID 0000-0002-1928-3878
Qian ChenDepartment of Pharmaceutical Sciences, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou, 310058, China.
Minjie ShenDepartment of Pharmaceutical Sciences, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou, 310058, China.
Yanrong ZhengDepartment of Pharmaceutical Sciences, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou, 310058, China.
Xiaohui FanDepartment of Pharmaceutical Sciences, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou, 310058, China.ORCID 0000-0002-6336-3007
Jie LiaoDepartment of Pharmaceutical Sciences, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou, 310058, China.

Funding

National Natural Science Foundation of China 82204772Noncommunicable Chronic Diseases-National Science and Technology Major Project 2024ZD0530704'Pioneer' and 'Leading Goose' R&D Program of Zhejiang 2024C03106Starlit South Lake Leading Elite Program 2023A303005Zhejiang Provincial Natural Science Foundation of China LD25H090002
6 · The paper itself

Abstract

Absorption, distribution, metabolism, excretion, and toxicity (ADMET) properties are critical determinants of the pharmacokinetic and safety profiles of drug candidates. Accurate and early-stage prediction of ADMET characteristics is essential for reducing late-stage attrition rates, lowering development costs, and accelerating the drug discovery process. Recent advances in deep learning have shown great promise in molecular property prediction, especially with the emergence of Transformer-based architectures that can effectively model long-range dependencies in molecular representations. However, most existing methods rely heavily on atom-level encodings (e.g. smiles or molecular graphs), which often lack structural interpretability and generalization across heterogeneous tasks. Previously, we developed a de novo and flexible molecular representation framework named MSformer (available at https://github.com/ZJUFanLab/MSformer), which demonstrated success in bioactivity prediction. We have now adapted and specialized this architecture for ADMET property prediction. This adapted implementation, designated as MSformer-ADMET, extends the framework's capabilities to pharmacokinetic and toxicity endpoints while maintaining its flexible, fragmentation-based approach to molecular representation learning. MSformer-ADMET is fine-tuned on 22 tasks collected from the Therapeutics Data Commons (TDC), covering both classification and regression settings. Results demonstrate that MSformer-ADMET achieves superior performance across a wide range of ADMET endpoints, consistently outperforming conventional smiles-based and graph-based models. Notably, we further conducted interpretability analyses by leveraging the model's attention distributions and fragment-to-atom mappings, allowing the identification of key structural fragments that are highly associated with molecular properties. This post hoc interpretability provides more transparent insights into the structure-property relationship. Collectively, results demonstrate that MSformer-ADMET is a highly effective and broadly applicable model for ADMET prediction.

Indexed as

Deep LearningDrug DiscoveryPharmacokineticsSoftwareHumansADMETdeep learningdrug discoverymeta structurenatural productstransformer

Identifiers

PMID41021261
PMCPMC12478026

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.